In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Institute for OneWorld Health

Latest From Institute for OneWorld Health

Deals Shaping the Medical Industry (11/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions

Executive Briefing - The neglected diseases challenge

Metabolic Disorders Gastrointestinal

RXi Pharmaceuticals makes board appointment

RXi Pharmaceuticals, a US biopharmaceutical company focused on the development and commercialisation of therapeutics based on RNAi, has appointed Dr Richard Chin, chief executive officer of the Institute for OneWorld Health, to its board of directors.


New appointment at Institute for OneWorld Health

The Institute for OneWorld Health, a US non-profit pharmaceutical company developing drugs for neglected infectious diseases in the developing world, has appointed Dr Menghis Bairu to its board of directors. He is executive vice-president, head of global development and chief medical officer for Elan.

See All

Company Information

  • Industry
  • Academic and Research Institutions